Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions.
Duminuco A, Nardo A, Orofino A, Giunta G, Conticello C, Del Fabro V, Chiarenza A, Parisi MS, Figuera A, Leotta S, Milone G, Cupri A, Cambria D, Di Raimondo F, Romano A, Palumbo GA.
Duminuco A, et al. Among authors: palumbo ga.
Cancer. 2024 Jan 1;130(1):41-50. doi: 10.1002/cncr.35005. Epub 2023 Sep 1.
Cancer. 2024.
PMID: 37658645